The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
Open accessAbstract
Background Improved clinical predictors for disease progression are needed for localized prostate cancer, where only a minority of patients experience poor outcomes. We undertake an unbiased large-scale analysis of genes associated with aggressive clinical course. Methods Prostate cancer samples, obtained from patients treated with radical prostatectomy at three academic institutions, were analyzed for gene expression using a clinical-grade, high-density Affymetrix GeneChip platform, encompassing >1 million genomic loci. Nomination of prognostic candidate genes was performed on a discovery cohort (n=545) and validated on three independent cohorts (n=463), totaling 1,008 patients. Molecular assays were performed in a CLIA-certified (Clinical Laboratory Improvement Amendments) laboratory facility. Multivariate analyses were performed for the primary endpoint of metastasis. The top prostate-specific gene was evaluated in urine samples from 230 patients using PCR. Findings Among all known genes, the long noncoding RNA SChLAP1 ranked first for elevated expression in patients with metastatic progression by receiver-operator-curve (ROC) area-under-the-curve (AUC) analyses. Of the top five prognostic genes, SChLAP1 was the only prostate-specific gene. Validation in three independent cohorts confirmed the prognostic value of SChLAP1 for metastasis. On multivariate modeling, SChLAP1 expression independently predicted metastasis within ten years (odds ratio (OR) = 2·45, 95% confidence interval (CI) 1·70 – 3·53), death within ten years (OR = 1·93, 95% CI 1·31 – 2·85), and biochemical recurrence within five years (OR = 1·76, 95% CI 1·28 – 2·41) with odds ratios comparable to Gleason score. Evaluation of SChLAP1 expression in 230 urine sediment samples with either biopsy-confirmed cancer or biopsy-negative tissue demonstrated increased incidence and expression of SChLAP1 RNA in patients at a higher risk for disease progression. Interpretation We perform the largest high-throughput, unbiased study of prostate cancer prognostic biomarkers to date and discover SChLAP1 as one of the best genes for the prediction of metastasis. We validate SChLAP1 extensively using a clinical-grade assay in a CLIA-certified laboratory. We show feasibility of a non-invasive urine test for SChLAP1, and suggest that SChLAP1 represents a very promising biomarker for aggressive clinical course. Funding Prostate Cancer Foundation, National Institutes of Health, Department of Defense, Early Detection Research Network, Doris Duke Charitable Foundation, and Howard Hughes Medical Institute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040297 · Cited by 8,613
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Vandenbroucke, J. P., Elm, E. V., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010-w1 · Cited by 3,543
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Self-citationREporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
Cited by
Long Noncoding RNAs in Cancer Pathways
Schmitt, A. M., & Chang, H. Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.010 · Cited by 2,992
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Self-citationProstate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Long noncoding RNAs in cancer metastasis
Liu, S. J., Dang, H. X., Lim, D. A., Feng, F. Y., & Maher, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00353-1 · Cited by 648
Self-citationWidespread and Functional RNA Circularization in Localized Prostate Cancer
Chen, S., Huang, V., Xu, X., Livingstone, J., Soares, F., Jeon, J., Zeng, Y., Hua, J. T., Petricca, J., Guo, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.025 · Cited by 544
Self-citation
Metadata
- Authors
- Prensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., Davicioni, E., Den, R. B., Dicker, A. P., Karnes, R. J., Wei, J. T., Klein, E. A., Jenkins, R. B., Chinnaiyan, A. M., & Feng, F. Y.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 15
- Issue
- 13
- Pages
- 1469-1480
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2031320118
- Cited by
- 264
- References
- 7
- FWCI
- 22.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71113-1
- The paper
- Prensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., Davicioni, E., Den, R. B., Dicker, A. P., Karnes, R. J., Wei, J. T., Klein, E. A., Jenkins, R. B., Chinnaiyan, A. M., & Feng, F. Y. (2014). RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71113-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.